Search Results - "Ghosh, Debopriya"

Enriched Random Forest for High Dimensional Genomic Data by Ghosh, Debopriya, Cabrera, Javier

“…Ensemble methods such as random forest works well on high-dimensional datasets. However, when the number of features is extremely large compared to the number…”
Get full text

Microplastics/nanoplastics released from facemasks as contaminants of emerging concern by Kaur, Mehakdeep, Ghosh, Debopriya, Guleria, Shikha, Arya, Shailendra Kumar, Puri, Sanjeev, Khatri, Madhu

“…Facemasks have become a global medical necessity and are a key preventive measure against COVID-19. Typically, facemasks (FMs) are fabricated from…”
Get full text

Data science, learning, and applications to biomedical and health sciences by Adam, Nabil R., Wieder, Robert, Ghosh, Debopriya

“…The last decade has seen an unprecedented increase in the volume and variety of electronic data related to research and development, health records, and…”
Get full text

Socio-economic impact on COVID-19 cases and deaths and its evolution in New Jersey by Amaratunga, Dhammika, Cabrera, Javier, Ghosh, Debopriya, Katehakis, Michael N., Wang, Jin, Wang, Wenting

“…Socio-economic factors could impact how epidemics spread. In this study, we investigated the possible effect of several local socio-economic factors on the…”
Get full text

Polystyrene nanoplastics: optimized removal using magnetic nano-adsorbent and toxicity assessment in zebrafish embryos by Kumar, Chaitanya, Singh, Harpreet, Ghosh, Debopriya, Jain, Atul, Arya, Shailendra Kumar, Khatri, Madhu

“…Purpose The presence of microplastics (MPs) and nanoplastics (NPs) in aquatic ecosystems has raised serious environmental and health concerns. Polystyrene is…”
Get full text

Hybrid continuous reassessment method with overdose control for safer dose escalation by Ghosh, Debopriya, Xie, Hong, Zhang, Liangcai, Chen, Fei, Mohanty, Surya, Li, Xiang

“…Phase 1 oncology studies focus on safety of novel treatments and identifying a dose associated with acceptable toxicity level. Various model-based designs have…”
Get full text

Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study by Matous, Jeffrey, Biran, Noa, Perrot, Aurore, Berdeja, Jésus G, Dorritie, Kathleen, Elssen, Janine Van, Searle, Emma, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, Thornton, Katherine, Smit, Damiette, Quach, Hang

“…Introduction: Talquetamab (tal) is a T-cell redirecting bispecific antibody (BsAb) targeting GPRC5D and CD3. GPRC5D is a novel antigen that is highly expressed…”
Get full text

Comparison of clinical and pathologic staging in esophageal cancer by Scholer, Anthony Joseph, Uppal, Abhineet, Ghosh, Debopriya, Kledzik, Mary, Santamaria-Barria, Juan, Khader, Adam, Fischer, Trevan D, Goldfarb, Melanie

“…Abstract only 31 Background: Randomized trials have demonstrated improved disease-free survival for more advanced esophageal cancer treated with neoadjuvant…”
Get full text

Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study by Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, Mason, Gary E, Renaud, Thomas, Matous, Jeffrey

Get full text

MM-349 Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study by Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, Mason, Gary E, Renaud, Thomas, Matous, Jeffrey

“…Tal is the first approved GPRC5D-targeting BsAb for treatment of patients with RRMM. Tal+pom led to rapid and deep responses in patients with RRMM. Report…”
Get full text

Inaccurate pretreatment staging can impact survival in early stage esophageal adenocarcinoma by Scholer, Anthony J., Uppal, Abhineet, Chang, Shu‐Ching, Ghosh, Debopriya, Garland‐ Kledzik, Mary, Santamaria‐Barria, Juan, Khader, Adam, Dehal, Ahmed, Fischer, Trevan, Goldfarb, Melanie

“…Background Given the survival advantage of neoadjuvant treatment for locally advanced esophageal cancer, accurate clinical staging is necessary. The aim of…”
Get full text

Exploring the Genomic Landscape of Hepatobiliary Cancers to Establish a Novel Molecular Classification System by Scholer, Anthony J, Marcus, Rebecca K, Garland-Kledzik, Mary, Ghosh, Debopriya, Ensenyat-Mendez, Miquel, Germany, Joshua, Santamaria-Barria, Juan A, Khader, Adam, Orozco, Javier I J, Goldfarb, Melanie

“…Taxonomy of hepatobiliary cancer (HBC) categorizes tumors by location or histopathology (tissue of origin, TO). Tumors originating from different TOs can also…”
Get full text

Comorbidity Patterns and Its Impact on Health Outcomes: Two-Way Clustering Analysis by Ghosh, Debopriya, Cabrera, Javier, Adam, Tarek N., Levounis, Petros, Adam, Nabil R.

“…Comorbidity greatly increases the complexity of managing disease in patients. Approximately 27 percent of the US population have two or more concurrent…”
Get full text

Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study by Leighl, Natasha B, Akamatsu, Hiroaki, Lim, Sun Min, Cheng, Ying, Minchom, Anna R, Marmarelis, Melina E, Sanborn, Rachel E, Chih-Hsin Yang, James, Liu, Baogang, John, Thomas, Massutí, Bartomeu, Spira, Alexander I, Lee, Se-Hoon, Wang, Jialei, Li, Juan, Liu, Caigang, Novello, Silvia, Kondo, Masashi, Tamiya, Motohiro, Korbenfeld, Ernesto, Moskovitz, Mor, Han, Ji-Youn, Alexander, Mariam, Joshi, Rohit, Felip, Enriqueta, Voon, Pei Jye, Danchaivijitr, Pongwut, Hsu, Ping-Chih, Silva Melo Cruz, Felipe José, Wehler, Thomas, Greillier, Laurent, Teixeira, Encarnação, Nguyen, Danny, Sabari, Joshua K, Qin, Angel, Kowalski, Dariusz, Nahit Şendur, Mehmet Ali, Xie, John, Ghosh, Debopriya, Alhadab, Ali, Haddish-Berhane, Nahor, Clemens, Pamela L, Lorenzini, Patricia, Verheijen, Remy B, Gamil, Mohamed, Bauml, Joshua M, Baig, Mahadi, Passaro, Antonio

“…Phase 3 studies of intravenous amivantamab demonstrated efficacy across -mutated advanced non-small cell lung cancer (NSCLC). A subcutaneous formulation could…”
Get full text